Syngene has confirmed expansion in its biologics unit

Syngene has confirmed expansion in its biologics unit and has added ADC bioconjugation capability, which basically means they can now support clients end-to-end — from discovery work all the way up to GMP manufacturing under one roof. The company also clarified that this investment is not large enough to be considered “material” under SEBI guidelines, so no separate disclosure threshold breach. Financial & Business Snapshot Revenues have been growing steadily with double-digit momentum in the last reported quarter PAT keeps improving along with better cost discipline Company continues to invest in new facilities — including US biologics setup and India R&D expansion It already works with top global pharma names on long-term contracts Valuation & Positioning Syngene trades at a premium P/E (50–60x range) — the market is clearly pricing high visibility + sticky pharma research work Business is capital-intensive and compliance-heavy, but switching cost for clients is high, which supports long-term relationships Risks Heavy dependence on key clients and renewal cycles Execution risk on new facilities (US/Bio/ADC) Regulatory surprises can always hit margin in this industry FX exposure and continuous capex can compress near-term returns